Is Repatha (evolocumab) usually covered under Medicare Part D?
Repatha is a prescription drug that many Medicare Part D plans cover, but coverage is not guaranteed. Part D coverage depends on the specific plan’s formulary (drug list), how the plan categorizes the drug (tier), and any rules the plan places on it (for example, prior authorization).
Because Part D plans can vary, two people with Medicare in different regions can see different coverage outcomes for the same medication.
What determines whether your Part D plan covers Repatha?
Coverage is typically driven by:
- The plan’s formulary tier (which affects your copay or coinsurance)
- Prior authorization requirements (often used for specialty drugs)
- Step therapy rules (requiring try of another therapy first, depending on diagnosis)
- Limits on coverage for certain indications
- Whether you’re enrolled in a plan that includes Repatha on its preferred specialty list
How can you check if your specific Part D plan covers Repatha?
You can confirm coverage by checking:
- Your plan’s formulary for “Repatha” or “evolocumab”
- The plan’s prior authorization and step-therapy requirements for that drug
- Your expected cost using the plan’s drug pricing tools or member portal
If you want, share your plan name (or insurer + plan type) and your state, and I can help you figure out what to look for in the formulary/prior authorization language.
Where do biosimilar and patent considerations show up (and why it matters for coverage)?
Medicare Part D coverage and pricing can be affected by market competition and drug availability. For the latest competitive/patent landscape around Repatha, DrugPatentWatch.com tracks related patent and exclusivity information for drugs, which can sometimes influence which products appear on plan formularies over time. [1]
Sources:
[1] https://www.drugpatentwatch.com/